Curriculum Vitae
Date of Birth: 05th Nov, 1971
Place Offenburg, Germany
1982 – 1991 Grimmelshausen – Gymnasium Offenburg
1993 – 2000 Johannes Gutenberg University Mainz
Studies of human medicine
2000 Approbation (M.D.) by the Government of Rheinland-Pfalz, Germany.
07/00 – 12/01 Dept. of Gynecology and Obstetrics, Hospital Ludwigshafen, (Head of Dept: Prof. Lehmann until December 2000; since January 2001 PD Dr. W. Weikel)
01/02 – 09/05 Dept. of Gynecology & Gyn. Oncology, HSK, Dr. Horst Schmidt Klinik, Wiesbaden. Training for Specialist of Gynecology and Obstetrics (Head of Dept: Prof. Dr. Andreas du Bois)
09/2005-2009 Dept. of Gynecology & Gyn. Oncology, HSK, Dr. Horst Schmidt Klinik, Wiesbaden. Training for Gynecologic Oncology (Head of Dept: Prof. Dr. A. du Bois)
07/06 – 12/10 Senior physician at Dept. of Gynecology & Gyn. Oncology, HSK, Dr. Horst Schmidt Klinik, Wiesbaden (Head of Dept: Prof. Dr. A. du Bois)
01/2011-7/2021 Deputy director at Dept. of Gyn. Oncology, Kliniken Essen Mitte Ev.Hyssensstiftung/Knappschafts GmbH (Head of Dept: Prof. Dr. A. du Bois)
Since 8/2021 Director of the Dept. of Gynecology & Gynecologic Oncology
Ev. Kliniken Essen Mitte, Essen, Germany
Qualifications:
2005: Specialist for Gynecology & Obstetrics
2009: Specialist for Gynecologic Oncology
Dissertation 15.05.01: In vitro testing of chemosensitivity of primary tumour cells. Johannes Gutenberg University Mainz, Institute of Toxicology, (PD Dr. J. G. Hengstler)
Thesis 13.07.2016: Wertigkeit und Prädiktion der Rezidiv-OP bei Ovarialkarzinom. Philipps-University Marburg.
APL-Professorship 02.12.2021: Philipps-University Marburg
Memberships and Positions:
- German Society of Gynecology and Obstetrics (DGGG): since 2002
- Leading group of the AGO Studiengruppe (AGO Study Group): since 2004
- Speaker of the AGO Study Group: since 2017
- European Society of Gynaecological Oncology (ESGO): since 2004
- European Network of Gynaecological Trial Groups (ENGOT)
- Representative of the AGO Study Group at Gynecologic Cancer Intergroup (GCIG): since 2007
- Chair of the Ovarian Cancer Committee of the GCIG: 2012-2016
- German Cancer Society (DKG): since 2005
- Arbeitsgemeinschaft Gynäkologische Onkologie (AGO): since 2006
- Kommission Ovar of the AGO: since 2006
- Commission of Clinical Studies in Oncology of the DKG: 2008
Clinical trials
Since 2002 Co-Investigator in multiple Phase I, II and III studies. Principal investigator of BIBW-2992 (Phase II), AGO-OVAR 10 (Phase III), AGO-OVAR 2.12 (Phase III), AGO-GYN 5 (Phase II), AGO-GYN 7 (Phase II), MIP-Study (Translational Research), Enzastaurin-Study (Phase II), ALLTO (Phase III), PACT (Phase III), Study 19, HECTOR, AGO-OVAR 16, AGO-OVAR 2.21 (Phase III), AGO-OVAR 2.22 (NOVA), AGO-OVAR 2.14, AGO-OVAR 2.15, AGO-OVAR 2.23 (SOLO 2), AGO-OVAR 2.25 (Gannet 53), AGO-OVAR 17, CARACO, PazoDoble, REGSA, AGO-OVAR 2.18, MM-121 (Ph II),
National/International Principal Investigator of AGO-OVAR OP.1 (DESKTOP I), AGO-OVAR OP.2 (DESKTOP II), AGO-OVAR OP.3 (LION), AGO-OVAR OP.4 (DEKSTOP III), AGO-OVAR OP.6 (ECLAT), AGO-GYN 7, AGO-OVAR 2.13, Novonordisk IL 21(Phase I/II), AGO-OVAR 12, AGO-TR 1, AGO-OVAR 19, AGO-OVAR 20 (PAOLA1), AGO-GYN 9 (Alienor). AGO-OVAR 2.23 (SOLO2), AGO-OVAR 2.29, AGO-OVAR 23 (DUO-O), AGO-OVAR 2.34 (Mirova), AGO-OVAR 2.40 (Bouquet), SORAYA,